New therapy for the prevention and prophylactic treatment of acute radiation syndrome

Expert Opinion on Investigational Drugs

Volumn 16, Issue 6, 2007, Pages 767-770

  Zenk, John L ^a  

^a Humanetics Corp   (United States)

Author keywords

Acute radiation syndrome; Haematopoietic syndrome; Ionising radiation; Medical radiation Countermeasures; Radioactive fallout; Radioprotection

Indexed keywords

BIO 300; BIOLOGICAL MARKER; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HEMOPOIETIC GROWTH FACTOR; ISOENZYME; PLACEBO; RADIOPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CELL DAMAGE; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; DNA DAMAGE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENZYME INHIBITION; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MORTALITY; NONHUMAN; RADIATION INJURY; RADIATION PROTECTION; RETICULOCYTE COUNT; SURVIVAL RATE;

ANIMALS; ANTIOXIDANTS; DRUGS, INVESTIGATIONAL; HUMANS; RADIATION INJURIES; RADIATION, IONIZING; RADIATION-PROTECTIVE AGENTS;

EID: 34250016830     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.6.767     Document Type: Editorial

References (4)

1. WASELENKO JK, MACVITTIE TJ, BLAKELY WF et al.: Medical Management of the Acute Radiation Syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann. Intern. Med. (2004) 140:1037-1051.
2. ENVIRONMENTAL PROTECTION AGENCY. Limiting values of radionuclide intake and air concentration and dose conversion factors for inhalation, submersion, and ingestion. Federal Guidance Report. USEPA, Washington DC, USA (1988) 11:EPA-520/1-88-020.
3. METTLER FA, VOELZ GL: Major radiation exposure - what to expect and how to respond. N. Engl. J. Med. (2002) 346(20):1554-1561.
4. PELLMAR TC, ROCKWELL S, AND THE RADIOLOGICAL/NUCLEAR THREAT COUNTERMEASURES WORKING GROUP: Priority list of research areas for radiological nuclear threat countermeasures. Radiat. Res. (2005) 163:115-123.